GNLX
Genelux Corporation Common Stock
NASDAQ: GNLX · HEALTHCARE · BIOTECHNOLOGY
$2.67
+6.80% today
Updated 2026-04-30
Market cap
$114.70M
P/E ratio
—
P/S ratio
14,337.86x
EPS (TTM)
$-0.86
Dividend yield
—
52W range
$2 – $9
Volume
0.2M
Genelux Corporation Common Stock (GNLX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $11.07M | $170000.00 | $8000.00 | $8000.00 |
| Revenue growth (YoY) | — | — | — | — | -98.5% | -95.3% | +0.0% |
| Cost of revenue | $477000.00 | $658000.00 | $895000.00 | $968000.00 | $1.02M | $903000.00 | $574000.00 |
| Gross profit | $-477000.00 | $-658000.00 | $-895000.00 | $10.10M | $-848000.00 | $-895000.00 | $-566000.00 |
| Gross margin | — | — | — | 91.3% | -498.8% | -11187.5% | -7075.0% |
| R&D | $7.53M | $6.23M | $6.32M | $9.08M | $12.77M | $19.00M | $19.85M |
| SG&A | $3.13M | $6.20M | $8.29M | $5.00M | $11.57M | $12.71M | $13.37M |
| Operating income | $-10.87M | $-12.42M | $-14.61M | $-3.01M | $-24.16M | $-31.70M | $-33.21M |
| Operating margin | — | — | — | -27.2% | -14214.7% | -396200.0% | -415175.0% |
| EBITDA | $-10.49M | $-11.76M | $-13.67M | $-1.73M | $-26.46M | $-28.97M | $-32.64M |
| EBITDA margin | — | — | — | -15.6% | -15562.9% | -362075.0% | -408000.0% |
| EBIT | $-10.87M | $-12.42M | $-14.56M | $-2.70M | $-27.48M | $-29.87M | $-33.21M |
| Interest expense | $761000.00 | $1.22M | $1.81M | $1.41M | $3.97M | $0.00 | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-11.63M | $-14.86M | $-17.80M | $-5.21M | $-28.30M | $-29.87M | $-32.15M |
| Net income growth (YoY) | — | -27.8% | -19.7% | +70.7% | -443.4% | -5.6% | -7.6% |
| Profit margin | — | — | — | -47.0% | -16645.3% | -373362.5% | -401812.5% |